PHARMAC has now completed national contracting for interventional cardiology products that are used in DHB hospitals across New Zealand. Work is underway to evaluate market share procurement opportunities for permanent coronary drug-eluting stents.
Consultation: Proposal to award market share for permanent coronary drug eluting stents in DHBs. Closes: 19 December 2018.
Included within the scope of interventional cardiology
- Access devices
- Ancillary devices
- Atherectomy devices
- Balloon catheters
- Coronary imaging systems
- Embolic protection devices
- Guide wires
- Structural devices – valves
- Structural health occluders & associated devices
- Therapeutic infusion system
- Vascular closure device
Suppliers under national contract
- Abbott Laboratories New Zealand
- Bio-Excel (Australia)
- Biotronik Australia
- Boston Scientific New Zealand
- Edwards Lifesciences (NZ) Limited
- Getinge Australia Pty Limited
- Intermed Medical
- Medtronic New Zealand
- N Stenning
- Obex Medical
- St Jude Medical
- Teleflex Medical New Zealand Limited
- Terumo Australia
List of contracted products
- for "interventional cardiology". Schedule document
- for "interventional cardiology". Schedule spreadsheet
Background and current state
PHARMAC invited suppliers to submit their registrations of interest to supply products in scope of this category in April 2014. From that process, PHARMAC has negotiated contracts with 12 suppliers. Our national contracting work in this category is now complete. PHARMAC is now exploring the next steps in this category.
- Registrations of Interest - Interventional cardiology (April 2014)
- RFP - Supply of permanent coronary drug-eluting stents (November 2017)
Seeking expert clinical advice is an important part of our work in medical devices. The Interventional Cardiology Advisory Group (ICAG) is made up of 10 clinicians who were appointed on the advice of the Cardiac Society of Australia and New Zealand, and other key stakeholders. The Group is providing PHARMAC objective clinical advice to assist in determining strategies going forward in regard to managing future assessment, standardisation, prioritisation and procurement of interventional cardiology devices.
Staying in touch
If you have any questions or would like to be kept up to date, please contact us at email@example.com, phone 0800 660 050, or sign up to receive our regular newsletter update Device Advice.
Last updated: 22 November 2018